Nanjing Xian-Janssen Pharmaceutical VS channel power and brand strength to see The Game.doc

 PAGE \* MERGEFORMAT 8 Nanjing Xian-Janssen Pharmaceutical VS channel power and brand strength to see The Game ‘2007 Years of April 28, China’s largest pharmaceutical business enterprises in Nanjing, one of medicine suspended into a joint venture to buy the country’s largest pharmaceutical companies Johnson amp;amp; Johnson all the medicines, require that ‘comprehensive dialogue’ approach with the Xi’an-Janssen negotiations and consultations to resolve the parties’ In 2007, contract negotiations, there is a conflict of interest ‘. ‘ This incident was due to appear on the surface distribution of Nanjing Medical costs are rising, falling profits caused by ordinary commercial disputes, and its essence is the channel power and brand strength in the game in the channels of the right to speak in the commercial chain, the increasing weight of another concrete expression, we can find out more through the event itself the value of market trends, and thus gain more enterprises in brand building and channel planning Significance! For the channel, the supplier has a strong brand with strong sales driven, high rate of cash flow small suppliers can not match advantage, while in the traditional way of thinking in the market, strong brand means that has the absolute right to speak (particularly in the face of the operation of the enterprise products as its lifeline, when more small and medium business channel is not an unassailable advantage), but the market should prove to the brand is not able to always take advantage of the strong! The rapid growth of the channel they had rewritten the role of the market at a disadvantage, when the channel master distribution suppliers considerable market share, the two sides had been doomed to a strong outcome of the dialogue, costs, profits fell just a fuse. Channel operators step by step, not only hope to achieve equity firms may be more room for development in the industrial chain, and to explore new profit model of in-depth strategi